GSK plc - 29 Jun 2021 Form 3 Insider Report for CVRx, Inc. (CVRX)

Role
10%+ Owner
Signature
Victoria Whyte, Authorized Signatory, GlaxoSmithKline plc
Issuer symbol
CVRX
Transactions as of
29 Jun 2021
Net transactions value
$0
Form type
3
Filing time
06 Jul 2021, 16:22:59 UTC
Previous filing
23 Jun 2021
Next filing
06 Jul 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVRX Series B-2 Preferred Stock 29 Jun 2021 Common Stock 1,505 See footnote F1, F2, F8
holding CVRX Series C-2 Preferred Stock 29 Jun 2021 Common Stock 12,979 See footnote F2, F3, F8
holding CVRX Series D-2 Preferred Stock 29 Jun 2021 Common Stock 14,917 See footnote F2, F4, F8
holding CVRX Series E-2 Preferred Stock 29 Jun 2021 Common Stock 8,380 See footnote F2, F5, F8
holding CVRX Series F-2 Preferred Stock 29 Jun 2021 Common Stock 27,345 See footnote F2, F6, F8
holding CVRX Series G Preferred Stock 29 Jun 2021 Common Stock 635,646 See footnote F2, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Series B-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series B-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F2 Share numbers give effect to the reverse split of each share of the Issuer's Common Stock into 0.0252857287 shares of Common Stock, effected on June 22, 2021, which will be effective for the Preferred Stock upon its conversion to Common Stock upon the closing of the Issuer's initial public offering.
F3 The shares of Series C-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series C-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F4 The shares of Series D-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series D-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F5 The shares of Series E-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series E-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F6 The shares of Series F-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series F-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F7 The shares of Series G Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series G Preferred Stock will automatically convert into 0.0632143218 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F8 The shares reported herein are held of record by Action Potential Venture Capital, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").